

| | | | |
|---|------------------------|-------------------|------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) | Application Number | | 10589840 |
| | Filing Date | | 2007-05-17 |
| | First Named Inventor | Maureen Caligiuri | |
| | Art Unit | 1628 | |
| | Examiner Name | A. Pagonakis | |
| | Attorney Docket Number | GPC-298.1P US | |

| U.S.PATENTS | | | | | | | Remove |
|-------------------|---------|---------------|------------------------|------------|---|--|--------|
| Examiner Initial* | Cite No | Patent Number | Kind Code ¹ | Issue Date | Name of Patentee or Applicant of cited Document | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear | |
| | 1 | | | | | | |

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

| U.S.PATENT APPLICATION PUBLICATIONS | | | | | | | Remove |
|-------------------------------------|---------|--------------------|------------------------|------------------|---|--|--------|
| Examiner Initial* | Cite No | Publication Number | Kind Code ¹ | Publication Date | Name of Patentee or Applicant of cited Document | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear | |
| | 1 | | | | | | |

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

| FOREIGN PATENT DOCUMENTS | | | | | | | | Remove |
|--------------------------|---------|--------------------------------------|-----------------------------|------------------------|------------------|---|--|--------------------------|
| Examiner Initial* | Cite No | Foreign Document Number ³ | Country Code ² i | Kind Code ⁴ | Publication Date | Name of Patentee or Applicant of cited Document | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear | T ⁵ |
| | 1 | | | | | | | <input type="checkbox"/> |

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

| NON-PATENT LITERATURE DOCUMENTS | | | | Remove |
|---------------------------------|---------|---|----------------|--------|
| Examiner Initials* | Cite No | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published. | T ⁵ | |
| | | | | |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | |
|------------------------|-------------------|
| Application Number | 10589840 |
| Filing Date | 2007-05-17 |
| First Named Inventor | Maureen Caligiuri |
| Art Unit | 1628 |
| Examiner Name | A. Pagonakis |
| Attorney Docket Number | GPC-298.1P US |

| | | |
|----|---|--------------------------|
| 1 | Calabresi et al., Section IX Chemotherapy of Neoplastic Diseases - Introduction, Goodman & Gilman's The Pharmacological Basis of Therapeutics 10th ed., (J. Hardman, L. Limbird, and A. Gilman eds.), (McGraw-Hill, New York, 2001) (pp. 1381, 1383-1385 and 1388 provided) | <input type="checkbox"/> |
| 2 | Engblom et al., "Additive and supra-additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines", British Journal of Cancer, 79(2): 286-292 (1999) | <input type="checkbox"/> |
| 3 | Engblom et al., "Carboplatin-Paclitaxel-and Carboplatin-Docetaxel-Induced Cytotoxic Effect in Epithelial Ovarian Carcinoma in Vitro", Cancer, 86: 2066-2073 (1999) | <input type="checkbox"/> |
| 4 | Fokkema et al., "JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin", Biochemical Pharmacology, 63: 1989-1996 (2002) | <input type="checkbox"/> |
| 5 | Gura, T., "Systems for Identifying New Drugs Are Often Faulty", Science, 278(5340): 1041-1042 (1997) | <input type="checkbox"/> |
| 6 | Kelland, L.R., "An update on satraplatin: the first orally available platinum anticancer drug", Exp. Opin. Invest. Drugs, 9 (6): 1373-1382 (2000) | <input type="checkbox"/> |
| 7 | Moreno et al., "Phase II study of docetaxel and cisplatin in first line treatment of disseminated small cell lung cancer (SCLC): Preliminary results", European Journal of Cancer, 35: S262 (1999) | <input type="checkbox"/> |
| 8 | Petrylak, D.P., "Docetaxel for the Treatment of Hormone-Refractory Prostate Cancer", Reviews in Urology, 5(Suppl. 2): S14-S21 (2003) | <input type="checkbox"/> |
| 9 | Van Putten et al., "Docetaxel and carboplatin combination as second-line treatment in metastatic non-small-cell lung cancer (NSCLC)", European Journal of Cancer, 37: S51 (2001) | <input type="checkbox"/> |
| 10 | Vogelstein et al., Chapter 1, In The Genetic Basis of Human Cancer 2nd ed., (B. Vogelstein and K. Kinzler eds.), (McGraw-Hill, 2002) p. 3. | <input type="checkbox"/> |

If you wish to add additional non-patent literature document citation information please click the Add button

| | | | |
|---|------------------------|-------------------|------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) | Application Number | | 10589840 |
| | Filing Date | | 2007-05-17 |
| | First Named Inventor | Maureen Caligiuri | |
| | Art Unit | 1628 | |
| | Examiner Name | A. Pagonakis | |
| | Attorney Docket Number | GPC-298.1P US | |

| EXAMINER SIGNATURE | | | |
|--|--|-----------------|--|
| Examiner Signature | | Date Considered | |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | |
| <small> ¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached. </small> | | | |